转移因子联合抗甲状腺药物治疗Graves病的临床观察
|
摘要
目的探讨转移因子与抗甲状腺药物综合治疗Graves病的临床效果。方法选取湖南省中医药高等专科学校附属医院收治的120例Graves病患者进行临床研究,随机分为两组,对两组患者进行饮食控制,禁止患者摄入碘,对照组常规服用抗甲状腺药物,实验组在对照组服用药物基础上加用转移因子药物。比较观察两组患者的临床效果。结果与对照组比较,实验组抗甲状腺药物达到最小维持量所需要的时间明显缩短(P<0.05);甲状腺缩小率明显提高(P<0.05);治疗过程中,侵润性突眼发生率、外周血白细胞减少、肝功异常及过敏反应发生率明显降低(P<0.05)。结论转移因子联合抗甲状腺药物在临床治疗过程中效果明显,可作为Graves病的辅助用药。
Objective To explore the clinical effect of transfer factor and antithyroid drugs in the treatment of Graves disease. Methods One hundred and twenty patients treated affiliated hospital of hunan college of traditional Chinese medicine in the last two years were studied and randomly divided into group A and group B.The two groups of patients were controlled by diet,the patients were forbidden to take iodine,group A was used as the control group,the routine antithyroid drug was applied,while group B was used as the experimental group,and the transfer factor was added on the basis of the group A.The clinical effects of two groups of patients were compared. Results Compared with the control group,the time needed for the minimum maintenance of antithyroid drugs was significantly shortened(P<0.05),and the thyroid reduction rate was significantly improved(P<0.05). During the whole treatment,the incidence of embellish exophthalmos,peripheral blood leukocyte reduction,liver dysfunction and the incidence of anaphylaxis were obviously decreased(P<0.05). Conclusion The transfer factor combined with antithyroid drugs is effective in clinical treatment,which can be further used as an adjuvant drug for Graves disease.
Objective To explore the clinical effect of transfer factor and antithyroid drugs in the treatment of Graves disease. Methods One hundred and twenty patients treated affiliated hospital of hunan college of traditional Chinese medicine in the last two years were studied and randomly divided into group A and group B.The two groups of patients were controlled by diet,the patients were forbidden to take iodine,group A was used as the control group,the routine antithyroid drug was applied,while group B was used as the experimental group,and the transfer factor was added on the basis of the group A.The clinical effects of two groups of patients were compared. Results Compared with the control group,the time needed for the minimum maintenance of antithyroid drugs was significantly shortened(P<0.05),and the thyroid reduction rate was significantly improved(P<0.05). During the whole treatment,the incidence of embellish exophthalmos,peripheral blood leukocyte reduction,liver dysfunction and the incidence of anaphylaxis were obviously decreased(P<0.05). Conclusion The transfer factor combined with antithyroid drugs is effective in clinical treatment,which can be further used as an adjuvant drug for Graves disease.
引文
[1]郭娟,韩慧芳,律静.免疫调节剂转移因子联合抗甲状腺药物治疗甲亢Graves病的临床观察[J].中国保健营养,2013,23(8):4215-4216.
[2]吕倩.急性冠脉综合征合并低促甲状腺素血症患者治疗及预后的研究[D].长沙:南方医科大学,2017.
[3]罗光涛.转移因子联合抗甲状腺药物治疗甲亢Graves病357例临床观察[J].实用医院临床杂志,2009,6(1):47-49.
[4]鲁剑梅.抗甲状腺药物治疗Graves病导致药物性甲状腺功能减退的临床研究[D].武汉:湖北中医药大学,2014.
[5]胡潇豪.抗甲状腺药物联合左旋甲状腺素治疗对Graves’s病的疗效观察及治疗后2年随访研究[D].长沙:南方医科大学,2015.
[6]林特夫.转移因子及其在肿瘤免疫治疗上的应用[J].蚌埠医学院学报,1978,3(s1):28-37.
[7]张显杰,李俊山,刘洁.猪脾转移因子口服液辅助治疗恶性肿瘤52例[J].广州医学院学报,2004,32(3):85-90.
[8]刘勇.转移因子联合双歧杆菌对鹅口疮患儿临床症状及免疫功能的影响[J].社区医学杂志,2017,15(7):61-63.
[2]吕倩.急性冠脉综合征合并低促甲状腺素血症患者治疗及预后的研究[D].长沙:南方医科大学,2017.
[3]罗光涛.转移因子联合抗甲状腺药物治疗甲亢Graves病357例临床观察[J].实用医院临床杂志,2009,6(1):47-49.
[4]鲁剑梅.抗甲状腺药物治疗Graves病导致药物性甲状腺功能减退的临床研究[D].武汉:湖北中医药大学,2014.
[5]胡潇豪.抗甲状腺药物联合左旋甲状腺素治疗对Graves’s病的疗效观察及治疗后2年随访研究[D].长沙:南方医科大学,2015.
[6]林特夫.转移因子及其在肿瘤免疫治疗上的应用[J].蚌埠医学院学报,1978,3(s1):28-37.
[7]张显杰,李俊山,刘洁.猪脾转移因子口服液辅助治疗恶性肿瘤52例[J].广州医学院学报,2004,32(3):85-90.
[8]刘勇.转移因子联合双歧杆菌对鹅口疮患儿临床症状及免疫功能的影响[J].社区医学杂志,2017,15(7):61-63.